Haleon
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 2022-01-01
- Employees
- 25.4K
- Market Cap
- -
- Website
- http://www.haleon.com
- Introduction
Haleon Plc engages in the provision of personal healthcare products. The firm focuses on consumer healthcare. It operates under the following geographical segments: North America, EMEA and LatAm, and Asia Pacific. The company was founded on July 18, 2022 and is headquartered in Weybridge, the United Kingdom.
Quantification of Diclofenac 2.32% (Voltaren) in Rinse Water After Different Application Methods
Not Applicable
Completed
- Conditions
- Healthy Participants
- Interventions
- Drug: Voltaren® Schmerzgel forte; 2.32% (Test Product)
- First Posted Date
- 2025-05-01
- Last Posted Date
- 2025-05-01
- Lead Sponsor
- HALEON
- Target Recruit Count
- 33
- Registration Number
- NCT06954181
- Locations
- 🇩🇪
SGS proderm GmbH, Schenefeld, Germany
A Clinical Study to Assess an Experimental Dentifrice in an Experimental Model of Early Stage Caries
Not Applicable
Recruiting
- Conditions
- Dental Caries
- Interventions
- Drug: Test DentifriceDrug: Reference DentifriceDrug: Negative Control Dentifrice
- First Posted Date
- 2025-04-29
- Last Posted Date
- 2025-05-09
- Lead Sponsor
- HALEON
- Target Recruit Count
- 50
- Registration Number
- NCT06949072
- Locations
- 🇺🇸
Oral Health Research Institute, Indianapolis, Indiana, United States
A Clinical Study to Evaluate the Efficacy of a Cetylpyridinium Chloride Mouthwash in Improving Gingival Health and Reducing Plaque Accumulation
Not Applicable
Recruiting
- Conditions
- Dental PlaqueGingivitis
- Interventions
- Drug: Crest Cavity Protection ToothpasteDrug: Experimental Mouthwash
- First Posted Date
- 2025-04-18
- Last Posted Date
- 2025-04-30
- Lead Sponsor
- HALEON
- Target Recruit Count
- 132
- Registration Number
- NCT06933368
- Locations
- 🇺🇸
Salus Research Inc, Fort Wayne, Indiana, United States
Bioequivalence Study of Paracetamol With Oral Single Dose Administration in Healthy Adult Subjects Under Fasting Conditions
Phase 1
Completed
- Conditions
- FeverPain
- Interventions
- Drug: Paracetamol ODTDrug: Alvedon film-coated tabletDrug: Panadol film-coated Tablet
- First Posted Date
- 2025-03-04
- Last Posted Date
- 2025-05-06
- Lead Sponsor
- HALEON
- Target Recruit Count
- 54
- Registration Number
- NCT06855576
- Locations
- 🇩🇪
SocraTec R&D GmbH, Erfurt, Thuringia, Germany
A Bioequivalence Study of Advil Dual Action Liquid Filled Capsules (125 mg/250 mg) Versus Advil Dual Action Caplets (125 mg/250 mg) and Bioavailability Assessment of Advil Dual Action Liquid Filled Capsules (125 mg/250 mg) and Advil Liqui-Gels (200 mg) in Healthy Adult Subjects
Phase 1
Completed
- Conditions
- Pain
- Interventions
- Drug: ADA Liquid Filled Capsules (Test Product)Drug: ADA Caplets (Reference Product)Drug: Advil Liqui-gels (Reference Product)
- First Posted Date
- 2025-01-31
- Last Posted Date
- 2025-04-23
- Lead Sponsor
- HALEON
- Target Recruit Count
- 54
- Registration Number
- NCT06802185
- Locations
- 🇺🇸
Spaulding Clinical, West Bend, Wisconsin, United States
Clinical Study to Investigate the Ability of a Stannous Fluoride Toothpaste to Protect From Dentine Hypersensitivity
Not Applicable
Active, not recruiting
- Conditions
- Dentin Sensitivity
- Interventions
- Drug: Sensodyne Rapid ReliefDrug: Colgate Cavity Protection
- First Posted Date
- 2024-12-13
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- HALEON
- Target Recruit Count
- 85
- Registration Number
- NCT06733285
- Locations
- 🇬🇧
University of Bristol, Bristol Dental School and Hospital, Bristol, United Kingdom
A Clinical Evidence Study Evaluating Quality of Life Parameters Following Treatment With Robitussin
Phase 4
Completed
- Conditions
- Common ColdCough
- Interventions
- Drug: Robitussin Maximum Strength Cough and Chest Congestion DMDrug: Robitussin Maximum Strength Nighttime Cough DM
- First Posted Date
- 2024-12-04
- Last Posted Date
- 2025-02-26
- Lead Sponsor
- HALEON
- Target Recruit Count
- 244
- Registration Number
- NCT06716645
- Locations
- 🇺🇸
Lindus Health Limited, New York, New York, United States
A Study to Evaluate the Efficacy of a Stannous Fluoride Toothpaste With a Cetylpyridinium Chloride Mouthwash in Improving Gingival Health and Reducing Plaque Accumulation
Not Applicable
Completed
- Conditions
- Dental PlaqueGingivitis
- Interventions
- Drug: Stannous Fluoride Toothpaste (Parodontax Complete Protection Toothpaste)Drug: Regular Fluoride Toothpaste (Crest Cavity Protection)Drug: CPC Mouthwash (Parodontax Active Gum Health Mouthwash)
- First Posted Date
- 2024-10-26
- Last Posted Date
- 2025-04-02
- Lead Sponsor
- HALEON
- Target Recruit Count
- 195
- Registration Number
- NCT06660069
- Locations
- 🇺🇸
Salus Research, Fort Wayne, Indiana, United States
A Study Evaluating Quality of Life Parameters Following Use of Emergen-C
Phase 4
Completed
- Conditions
- Dietary Supplements
- First Posted Date
- 2024-10-23
- Last Posted Date
- 2025-03-11
- Lead Sponsor
- HALEON
- Target Recruit Count
- 299
- Registration Number
- NCT06654089
- Locations
- 🇺🇸
Lindus Health Limited, New York, New York, United States
A Clinical Study Assessing the Effects of a Marketed Dentifrice on Tooth Sensitivity While Undergoing Tooth Bleaching
Phase 4
Completed
- Conditions
- Dentin Sensitivity
- Interventions
- Drug: Test Dentifrice (Sensodyne Repair and Protect Original Mint)Drug: Positive Control Dentifrice (Sensodyne Fresh Mint)Drug: Reference Dentifrice (Crest Cavity Protection Regular)
- First Posted Date
- 2024-09-23
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- HALEON
- Target Recruit Count
- 90
- Registration Number
- NCT06608368
- Locations
- 🇨🇦
All Sum Research, Mississauga, Ontario, Canada
© Copyright 2025. All Rights Reserved by MedPath